Uroplasty (UPI) Given Daily Media Impact Rating of 0.04

News articles about Uroplasty (NASDAQ:UPI) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Uroplasty earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 45.3061026684561 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Uroplasty (NASDAQ UPI) remained flat at $$1.22 during midday trading on Friday. Uroplasty has a 12-month low of $1.05 and a 12-month high of $4.05. The company has a market capitalization of $27.68, a PE ratio of -4.07 and a beta of -1.26.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://sportsperspectives.com/2018/02/09/uroplasty-upi-given-daily-media-impact-rating-of-0-04.html.

Uroplasty Company Profile

Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.

Insider Buying and Selling by Quarter for Uroplasty (NASDAQ:UPI)

Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply